secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2024-02-21T23:59:59+00:00
Accession:  0000950170-24-017568
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics 2023: CASGEVY approved in 5 countries; Q4 net income $89.3M
-------------------------------------------------------------------------------

- CASGEVY (exa-cel) approved in U.S., EU, Great Britain, Bahrain, KSA for SCD and TDT; ~35,000 patients in U.S. and Europe.
- Q4 net income $89.3M vs net loss $110.6M in Q4 2022; cash $1.7B at year-end, pro-forma >$2.1B after $200M milestone and $280M offering.
- Clinical trials ongoing for next-gen CAR T (CTX112, CTX131) and in vivo programs (CTX310, CTX320); CTX112 trial in SLE planned H1 2024.
- R&D expenses $95.1M in Q4 (down from $103.6M), G&A $16.5M (down from $21.2M); collaboration expense net $20M.
- Vertex paid $170M in 2023 milestones; eligible for additional $160M milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/0000950170-24-017568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024017568/crsp-20240221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-017568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer